Tudorza FDA Approval History
FDA Approved: Yes (First approved July 23, 2012)
Brand name: Tudorza
Generic name: aclidinium bromide
Dosage form: Pressair
Company: Allergan plc
Treatment for: COPD
Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Development timeline for Tudorza
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.